2 deoxy 2 fluoro l fucose

Manufactured by Biosynth

Sourced in United States

2-deoxy-2-fluoro-l-fucose is a carbohydrate derivative that serves as a synthetic precursor for various applications. It provides a structural building block for the development of complex molecules and compounds.

Automatically generated - may contain errors

Lab products found in correlation

Penicillin, by Thermo Fisher Scientific (1 mentions) Caco 2 cell line, by American Type Culture Collection (1 mentions) A549 cell line, by American Type Culture Collection (1 mentions) Fetal bovine serum (fbs), by Thermo Fisher Scientific (1 mentions) Dithiothreitol (dtt), by Merck Group (1 mentions) Iodoacetamide, by Merck Group (1 mentions) Eagle s minimum essential medium emem, by American Type Culture Collection (1 mentions) Sequencing grade modified trypsin, by Promega (1 mentions) Neuraminidase n2876, by Merck Group (1 mentions) Endoglycosidase h, by Merck Group (1 mentions) Kifunensine, by Merck Group (1 mentions) Swainsonine, by Merck Group (1 mentions) Sialyltransferase inhibitor 3 fax peracetyl neu5ac, by Merck Group (1 mentions)

Spelling variants of this product

L-fucose (6 citations) 2-deoxy-2-fluoro-l-fucose (2FF) (2 citations)

2 protocols using 2 deoxy 2 fluoro l fucose

Glycosylation Inhibitors for Cell Culture

Check if the same lab product or an alternative is used in the 5 most similar protocols

Caco-2 cell lines, A549 cell lines, and Eagle’s Minimum Essential Medium (EMEM) were obtained from the American Type Culture Collection (ATCC), Manassas, VA, USA. Dithiothreitol (DTT), iodoacetamide (IAA), and a human immortalized prostate PNT2 cell line were purchased from Sigma-Aldrich, St. Lousi, MO, USA. Phosphate-Buffered Saline (PBS), Roswell Park Memorial Institute (RPMI) 1640 medium, fetal bovine serum (FBS), and penicillin were purchased from ThermoFisher Scientific, Waltham, MA, USA. Sequencing Grade Modified Trypsin was purchased from Promega. Glycosylation inhibitors Kifunensine, 2-deoxy-2-fluoro-l-fucose, 6-alkynyl fucose, and 2,4,7,8,9-Penta-O-acetyl-N-acetyl-3-fluoro-b-d-neuraminic acid methyl ester were purchased from Carbosynth, San Diego, CA, USA.

Zhou Q., Xie Y., Lam M, & Lebrilla C.B. (2021). N-Glycomic Analysis of the Cell Shows Specific Effects of Glycosyl Transferase Inhibitors. Cells, 10(9), 2318.

+ Open protocol

+ Expand

Glycan Modulation and Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

UGCG inhibitors MZ31 (used concentration: 2μM), MZ21 (2μM), miglustat (100μM) were produced as previously described (Ghisaidoobe et al., 2014 (link)) and eliglustat (200nM) was obtained from Bio-Connect. Swainsonine (20μg/mL) and kifunensine (20μM) were obtained from Sigma. N-glycosylation inhibitor activity was confirmed by incubating W6/32 immunoprecipitated HLA-I molecules with Endoglycosidase H (Sigma) in a 20μl reaction mixture (50μM Sodiumcitrate (pH5.5), 0.2% SDS, 2μl Endoglycosidase H and protease inhibitors) for 18h at 37°C followed by HLA-I detection on immunoblot. Sialyltransferase inhibitor (3Fax-peracetyl Neu5Ac, 100μM) was obtained from Sigma and fucosyltransferase inhibitor (2-Deoxy-2-fluoro-L-fucose, 100μM) was obtained from Carbosynth. Cells were cultured for 2 or 3 days at 37°C with inhibitors and analyzed by flow cytometry. Cells were incubated with neuraminidase (N2876, Sigma, 225mU/mL) for 1h at 37°C.

Jongsma M.L., de Waard A.A., Raaben M., Zhang T., Cabukusta B., Platzer R., Blomen V.A., Xagara A., Verkerk T., Bliss S., Kong X., Gerke C., Janssen L., Stickel E., Holst S., Plomp R., Mulder A., Ferrone S., Claas F.H., Heemskerk M.H., Griffioen M., Halenius A., Overkleeft H., Huppa J.B., Wuhrer M., Brummelkamp T.R., Neefjes J, & Spaapen R.M. (2020). The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity, 54(1), 132-150.e9.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!